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Introduction {#sec1}
============

Mitochondria are double-membrane-bound subcellular organelles required for numerous cellular functions. In response to metabolic and physiological signals, mitochondria undergo fusion and fission, processes that are catalyzed by conserved GTP-hydrolyzing enzymes and their associated proteins ([@bib9]). Fission of mitochondria is needed for their fragmentation. This is triggered by dynamin 1-like protein (DNM1L), a cytoplasmic protein that is recruited to the mitochondrial surface where it constricts mitochondrial tubules. Fusion of the outer membranes is catalyzed by mitofusin 1 and 2 (MFN1, MFN2), whereas fusion of the mitochondrial inner membranes is catalyzed by the mitochondrial dynamin-like GTPase optic atrophy 1 (OPA1). Due to RNA splicing and protein processing, different isoforms of OPA1 exist. The long isoforms localize to the mitochondrial inner membrane through their transmembrane domains, whereas the short isoforms are expressed as soluble proteins in the mitochondrial intermembrane space. A balance of long and short OPA1 isoforms is required to maintain a healthy mitochondrial network ([@bib15], [@bib31]).

OPA1 is crucial for tissue development. *Opa1* heterozygous animals are viable, but experience a progressive loss of retinal ganglion cells (RGCs), optic nerve degeneration, and abnormal brain development ([@bib12], [@bib2]), whereas *Opa1*-null mice die early during embryonic development due to growth retardation and morphological abnormalities ([@bib12], [@bib2]). In humans, heterozygous mutations in *OPA1* cause the most common form of autosomal dominant optic atrophy (ADOA), a neuropathy wherein the majority of patients experience impaired vision ([@bib17], [@bib3]). Homozygous mutations in *OPA1* result in severe and fatal infantile disorders with neurodevelopmental deficits, multi-organ complications, encephalopathy, cardiomyopathy, and optic atrophy ([@bib40], [@bib36]).

To elucidate the molecular mechanisms by which OPA1 contributes to human neural development, we used *OPA1* haploinsufficient pluripotent stem cell lines and differentiated them into neural progenitor cells (NPCs) and forebrain neurons. Although we were able to generate NPCs and glutamatergic neurons, *OPA1* haploinsufficiency interfered with GABAergic interneuron formation. We then explored the molecular changes associated with the observed altered neural cell specification and identified a novel function for OPA1.

Results {#sec2}
=======

*OPA1* Haploinsufficiency Induces Oxidative Stress in hESCs {#sec2.1}
-----------------------------------------------------------

To study the role of OPA1 during neural development, we used human embryonic stem cells (hESCs) and the CRISPR-Cas9 gene editing technology and deleted a stretch of nucleotides, which induces a frameshift and a premature stop codon in the second exon of the *OPA1* transcript ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Because the majority of human disorders linked to *OPA1* are caused by heterozygous mutations, we targeted one allele only. We found a 50% reduction in *OPA1* mRNA transcript levels in heterozygous *OPA1+/−* compared with *OPA1+/+* hESCs, confirming that only one *OPA1* allele was transcribed ([Figure 1](#fig1){ref-type="fig"}A). The reduction in mRNA expression levels correlated with a 50% reduction in OPA1 protein levels in hESCs, indicating a non-sense-mediated RNA decay in *OPA1*+/− cells ([Figures 1](#fig1){ref-type="fig"}B and 1C). Expression levels of OCT4 and NANOG were comparable between *OPA1*+/− and parental hESCs, as shown by immunostaining and immunoblotting ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Moreover, hESC proliferation rates, assessed by automated live-cell analysis system, were similar between the two genotypes ([Figure S1](#mmc1){ref-type="supplementary-material"}D). To further analyze cell cycle dynamics in *OPA1*+/− hESCs, we performed flow cytometry (fluorescence-activated cell sorting \[FACS\]) analysis of hESCs labeled with the fluorescent DNA-intercalating dye propidium iodide (PI) and Ki-67 antibody. The ratio of cells in G0/G1, S, and G2/M phases ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F), as well as Ki-67 labeling ([Figure S1](#mmc1){ref-type="supplementary-material"}G), were similar between *OPA1*+/+ and *OPA1*+/− hESC, indicating that *OPA1* haploinsufficiency does not affect pluripotency or proliferation rates in hESCs. Using transmission electron microscopy (TEM), we then assessed mitochondrial morphology and distribution in *OPA1+/−* hESCs. The TEM images showed no obvious differences in mitochondrial morphology between *OPA1+/+* and *OPA1+/−* hESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Next, we measured mitochondrial length in *OPA1+/+* and *OPA1+/−* hESCs and binned the data into categories of intervals. Although this analysis revealed no significant change, we found a trend of more fragmented mitochondria in *OPA1+/−* hESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We therefore determined the circumference of mitochondria, and found a small, but significant decrease in circumference in *OPA1+/−* compared with *OPA1+/+* hESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}C). In addition, we found a significant increase in the intercristae distance in *OPA1+/−* compared with *OPA1+/+* hESCs ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). Mitochondria-targeted GFP (mito-GFP)-transduced hESCs also demonstrated that there was no obvious difference in mitochondrial shape or size among the two genotypes ([Figure S2](#mmc1){ref-type="supplementary-material"}F). The mitochondrial DNA content, as analyzed by copy number of the mitochondrial genes NADH-ubiquinone oxidoreductase chain 1 (*MT-ND1*) and *MT-ND4,* was similar between *OPA1+/+* and *OPA1*+/− hESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}G). Using mitochondrial respiration assays, we found similar ATP production and basal respiration rates ([Figures 1](#fig1){ref-type="fig"}D and 1E) and an increase in maximal respiration in *OPA1*+/− compared with *OPA1*+/+ hESCs ([Figures 1](#fig1){ref-type="fig"}D and 1E). Next, we analyzed whether reactive oxygen species (ROS) were altered in *OPA1*+/− hESCs. Flow cytometry analysis using the hydrogen peroxide-sensitive ROS indicator CM-H2DCFDA revealed significantly increased ROS levels in *OPA1*+/− compared with *OPA1*+/+ hESCs ([Figures 1](#fig1){ref-type="fig"}F and 1G). Taken together, our results reveal subtle changes in the mitochondrial morphology and increased levels of ROS in *OPA1* haploinsufficient hESCs.Figure 1*OPA1* Haploinsufficiency Induces Oxidative Stress in hESCs(A) *OPA1* mRNA expression levels in hESCs determined by qRT-PCR analysis.(B) Representative immunoblotting images showing OPA1 protein levels in hESCs, week 3 NPCs, and neurons. Beta-actin was used as loading control.(C) Densitometric analysis of immunoblots in *OPA1+/+* and *OPA1*+/− cells. Mean ± SEM, N = 4 independent experiments.(D) Oxygen consumption rate changes under mitochondrial stress in *OPA1*+/+ and *OPA1*+/− hESCs. Oligomycin, FCCP, antimycin, and rotenone were sequentially applied. Mean ± SEM, N = 2 independent experiments.(E) Basal respiration rates, maximum respiration rates, and ATP production calculated in *OPA1+/+* and *OPA1*+/− hESCs. Mean ± SEM, N = 2 independent experiments were performed and N ≥ 9 technical replicates were analyzed for each genotype. Student\'s t test was used to analyze the difference between two groups. n.s. not significant. ∗p \< 0.05.(F) Representative flow cytometry analysis of *OPA1*+/+ and *OPA1*+/− hESCs labeled with the hydrogen peroxide-sensitive oxidative stress indicator CM-H2DCFDA. Unlabeled hESCs (−) were used as negative control. hESCs that were incubated with 0.5 mM H~2~O~2~ were used as positive control.(G) Quantification of flow cytometry measurements in *OPA1+/+* and *OPA1*+/− hESCs. Arithmetic mean values were normalized to the values of labeled *OPA1+/+* hESCs.Mean ± SEM, N ≥ 3 independent experiments and N = 2 technical replicates. Student\'s t test was used to analyze difference between two groups. n.s. not significant. ∗∗p \< 0.01, ∗∗∗p \< 0.001. See also [Figures S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}.

*OPA1* Expression Is Upregulated during Neural Differentiation {#sec2.2}
--------------------------------------------------------------

Next, we investigated how *OPA1* heterozygosity affects neural differentiation. Using the dual SMAD inhibition protocol ([@bib8], [@bib39]), hESCs were differentiated into neuroepithelial progenitors and NPCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A). On day 11 of the differentiation protocol, neural commitment was evident by morphological transformation and expression of the neural stem cell marker PAX6 (day 11 NPCs, [Figure S3](#mmc1){ref-type="supplementary-material"}B). After passaging and further differentiation, PAX6-positive NPCs reorganized themselves into neural rosette structures (week 3 NPCs, [Figure S3](#mmc1){ref-type="supplementary-material"}C) before being differentiated into beta-tubulin III-positive neurons ([Figure S3](#mmc1){ref-type="supplementary-material"}D). To assess the neurogenic ability of hESCs, we first compared rosette formation of NPCs. Immunostainings showed that *OPA1*+/− NPCs formed tight junction protein Zonula-occludens-1 (ZO-1)-positive rosette structures with comparable efficiency as *OPA1*+/+ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}E). As the self-organization of neural rosettes is reminiscent of neural tube formation from neuroepithelium ([@bib14]), these results reveal that early neural development is not affected by *OPA1* haploinsufficiency.

Quantification of *OPA1* transcript levels by qRT-PCR showed a 25% increase of total *OPA1* mRNA levels during neuronal differentiation ([Figure S4](#mmc1){ref-type="supplementary-material"}A). *OPA1* is alternatively spliced in different tissues. Of these splice variants, *OPA1* transcript variant 1 (NM_015560), which lacks exons 4b and 5b ([Figure S1](#mmc1){ref-type="supplementary-material"}A), is the most abundantly expressed isoform in the mouse brain and retina ([@bib16], [@bib1]). In line with this, we found that *OPA1* isoform 1 levels markedly increased in our neuronal cultures ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Moreover, we found that isoform 1 became the predominant splice form during neural differentiation. In hESCs, the ratio of transcript variant 1 to total *OPA1* mRNA levels was approximately 1:1, whereas in neurons the majority of *OPA1* transcripts were isoform 1 ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Immunoblotting experiments showed a 25% and 2-fold increase of OPA1 protein in *OPA1+/+* NPCs and neurons when compared with hESCs, respectively ([Figures 1](#fig1){ref-type="fig"}B, 1C, and [S4](#mmc1){ref-type="supplementary-material"}D).

*OPA1* Heterozygous NPCs Fail to Generate DLX1/2+ Neurons {#sec2.3}
---------------------------------------------------------

To investigate the role of OPA1 during differentiation and neuronal function further, we analyzed neurons derived from *OPA1+/+* and *OPA1*+/− NPCs. Immunostaining experiments showed that pan-neuronal marker beta-tubulin III-positive neurons could be efficiently generated from both genotypes, indicating that *OPA1* haploinsufficiency is not affecting overall neuronal development ([Figure 2](#fig2){ref-type="fig"}A). Patch-clamp experiments demonstrated that *OPA1* haploinsufficiency did not interfere with the ability of neurons to fire action potentials in response to current stimuli ([Figure 2](#fig2){ref-type="fig"}B). To determine neuronal lineage specification, we selected T-box brain 1 (*TBR1*) as a marker for glutamatergic neurons ([@bib21]), and *DLX1* and *DLX2* as they are important for specification of RGCs and GABAergic neurons ([@bib4], [@bib28], [@bib13]). As expected, *TBR1*, *DLX1,* and *DLX2* mRNA expression levels increased during the neuronal differentiation of *OPA1*+/+ hESCs ([Figures 2](#fig2){ref-type="fig"}C--2E), demonstrating that our neuronal cultures included cell types representing forebrain development. During neuronal differentiation of *OPA1*+/− hESCs, we found that *TBR1* was expressed at similar levels as in *OPA1+/+* cells ([Figure 2](#fig2){ref-type="fig"}C). However, *OPA1*+/− cells notably failed to induce mRNA expression of *DLX1* and *DLX2* during neuronal maturation ([Figures 2](#fig2){ref-type="fig"}D and 2E). Using immunostaining, we showed that there were significantly less DLX2 immunoreactive cells in *OPA1*+/− compared with *OPA1+/+* neuronal cultures ([Figures 2](#fig2){ref-type="fig"}F and 2G). The absence of DLX2 protein in lysates of *OPA1*+/− but not *OPA1*+/+ neurons was further confirmed using immunoblotting ([Figure 2](#fig2){ref-type="fig"}H). Neurons derived from both genotypes expressed comparable levels of beta-tubulin III protein ([Figure 2](#fig2){ref-type="fig"}H).Figure 2*OPA1* Heterozygous NPCs Fail to Generate DLX1/2+ Neurons(A) Beta-tubulin III (TUJ1) staining of neurons. Scale bar, 100 μm.(B) Representative traces of patch-clamped neurons. Action potentials were elicited in *OPA1*+/+ and *OPA1+/−* neurons upon depolarizing current injection. Black bar indicates time of depolarizing current injection.(C--E) (C) *TBR1*, (D) *DLX1*, and (E) *DLX2* mRNA levels determined by qRT-PCR analyses in *OPA1*+/+ and *OPA1*+/− hESCs, NPCs, and neurons. Mean ± SEM, N ≥ 3 independent experiments for each genotype and cell type.(F) Immunostaining images of *OPA1*+/+ and *OPA1*+/− neurons. DAPI was used to stain nuclei. Scale bar, 100 μm.(G) Quantification of DLX2+ neurons. Mean ± SEM, N = 3 independent experiments.(H) Immunoblotting showing OPA1, DNM1L, GAD1/GAD67, DLX2, and beta-tubulin III protein expression in *OPA1+/+* and *OPA1*+/− hESCs and neurons. Beta-actin was used as loading control.Student\'s t test was used to analyze difference between two groups. n.s. not significant. ∗p \< 0.05, ∗∗∗p \< 0.001. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

*OPA1* Haploinsufficient NPCs Do Not Give Rise to GABAergic Interneurons {#sec2.4}
------------------------------------------------------------------------

DLX1 and DLX2 are transcription factors (TFs) important for GABAergic interneuron and RGC development ([@bib28], [@bib4], [@bib13]). As their downregulation indicated an altered neuronal function and differentiation potential when *OPA1* was reduced, we performed RNA sequencing (RNA-seq) in 7-week-old neurons. We found several genes encoding for TFs with known function in neurogenesis differentially regulated in *OPA1+/−* neurons ([Table S1](#mmc2){ref-type="supplementary-material"}). For instance, *FOXG1*, *DLX1*, *DLX2*, *DLX5*, and *DLX6* were genes highly downregulated in *OPA1*+/− compared with *OPA1+/+* neurons ([Figure 3](#fig3){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). Moreover, expression of *SFRP1* and *SEMA5A*, which are known to control RGC development and axonal growth, as well as *CTIP2/BCL11B* and *NEUROD6,* which are TFs that are highly expressed in the developing brain and retinal cells ([@bib10]), were also significantly downregulated. Other genes downregulated included *SLITRK2, SLITRK4,* and *SLITRK6*, which are plasma membrane proteins expressed in the retina, and several GABA receptor subunits (*GABRA2*, *GABRA4*, *GABRB1*, and *GABRG1*). Among the upregulated genes in *OPA1*+/− neurons we found *NR2F1*, *NR2F2,* and *NEUROD4,* which are TFs known to regulate cell fate specification in the retina ([Figure 3](#fig3){ref-type="fig"}A).Figure 3*OPA1* Haploinsufficient NPCs Do Not Give Rise to GABAergic Interneurons(A) Log~2~ fold-change and expression heatmaps of selected down- (green) and up- (red) regulated genes in *OPA1*+/− compared with *OPA1+/+* neurons. FC = fold-change. Expression intensities are displayed from blue (low expression) to yellow (high expression).(B) Immunoblotting showing OPA1, DNM1L, TBR1, and GAD1/GAD67 protein expression in *OPA1+/+* and *OPA1*+/− hESCs and neurons. OCT4 was used as pluripotency marker; beta-actin was used as loading control.(C) Densitometric analysis of GAD1 protein levels in *OPA1*+/+ and *OPA1*+/− neurons. Mean ± SEM, N = 2 independent experiments.(D) Immunoblotting showing GAD2/GAD65 and beta-tubulin III protein expression in *OPA1+/+* and *OPA1*+/− hESCs and neurons.(E) Densitometric analysis of GAD2 protein levels in *OPA1*+/+ and *OPA1*+/− neurons. Mean ± SEM, N = 2 independent experiments.Student\'s t test was used to analyze difference between two groups. ∗∗∗p \< 0.001. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}, and [Table S1](#mmc2){ref-type="supplementary-material"}.

The absence of DLX1/2 expression in *OPA1*+/− neurons prompted us to further investigate GABAergic neuronal markers. Glutamate decarboxylase 1 (GAD1/GAD67) and 2 (GAD2/GAD65), which catalyze the production of GABA from L-glutamic acid, were expressed in *OPA1+/+* neurons, whereas they were absent or markedly reduced in *OPA1*+/− neurons ([Figures 3](#fig3){ref-type="fig"}B--3E and [S4](#mmc1){ref-type="supplementary-material"}E). TBR1 and beta-tubulin III were expressed at comparable levels ([Figures 3](#fig3){ref-type="fig"}B and 3D). Overall, our transcriptional analysis demonstrates that reduced OPA1 protein levels alter the expression of genes that are important for GABAergic interneuron formation and retinal development.

We imaged mito-GFP-transduced neurons to assess mitochondrial morphology. Confocal microscopy analysis demonstrated that mitochondrial morphology and distribution were similar in *OPA1*+/− and *OPA1*+/+ neurons ([Figure 4](#fig4){ref-type="fig"}A). Quantification of mitochondrial length and binning of measurements into categories of intervals showed no evident differences in mitochondrial distribution ([Figures 4](#fig4){ref-type="fig"}B and 4C). Next, we analyzed energy metabolism in *OPA1*+/− and *OPA1*+/+ neuronal cultures using mitochondrial respiration assays. Our data revealed that neurons exhibited an increased mitochondrial respiration compared with hESCs ([Figure 4](#fig4){ref-type="fig"}D). However, basal respiration, maximal respiration, and ATP production rates were similar in *OPA1+/−* and *OPA1+/+* neurons ([Figure 4](#fig4){ref-type="fig"}E), suggesting that *OPA1* haploinsufficiency does not affect mitochondrial respiration in neurons. We then investigated oxidative stress levels in neuronal cultures. Flow cytometry analysis showed significantly increased ROS levels in *OPA1+/−* compared with *OPA1+/+* neurons ([Figures 4](#fig4){ref-type="fig"}F and 4G). FACS analysis of neurons labeled with the early apoptosis indicator Annexin V and late apoptosis indicator PI ([Figure 4](#fig4){ref-type="fig"}H) demonstrated no differences in apoptosis in neuronal culture conditions ([Figures 4](#fig4){ref-type="fig"}I and 4J). Importantly, when neurons were exposed to stress by pre-treatment with hydrogen peroxide we observed significantly more Annexin V+ cells in *OPA1+/−* compared with *OPA1+/+* neurons ([Figures 4](#fig4){ref-type="fig"}I and 4J).Figure 4*OPA1* Haploinsufficiency Induces Oxidative Stress and Apoptosis in Neurons(A) Confocal microscopic images of mito-GFP-transduced *OPA1*+/+ and *OPA1*+/− neurons. ∗ denotes nucleus. Scale bar, 10 μm.(B) Quantification of mitochondria length in *OPA1+/+* and *OPA1*+/− neurons. N = 680 mitochondria for *OPA1*+/+ and N = 645 mitochondria for *OPA1*+/− were measured.(C) Mitochondrial length was measured and binned into categories of length intervals.(D) Oxygen consumption rate changes under mitochondrial stress in *OPA1*+/+ and *OPA1*+/− neurons. Oligomycin, FCCP, antimycin, and rotenone were sequentially applied. Mean ± SEM, N = 2 independent experiments.(E) Basal respiration rates, maximum respiration rates, and ATP production calculated in *OPA1+/+* and *OPA1*+/− neurons. Mean ± SEM, N = 2 independent experiments were performed and N ≥ 40 technical replicates were analyzed for each genotype.(F) Representative flow cytometry analysis of *OPA1*+/+ and *OPA1*+/− neurons labeled with the hydrogen peroxide-sensitive oxidative stress indicator CM-H2DCFDA. Unlabeled neurons (−) were used as negative control. Neurons that were incubated with 0.5 mM H~2~O~2~ were used as positive control.(G) Quantification of flow cytometry measurements in *OPA1+/+* and *OPA1*+/− neurons. Arithmetic mean values were normalized to the values of labeled *OPA1+/+* neurons. Mean ± SEM, N ≥ 3 independent experiments and N = 2 technical replicates.(H) Representative flow cytometry analysis of live *OPA1*+/+ and *OPA1*+/− neurons labeled with the early apoptosis indicator annexin V and late-apoptosis indicator propidium iodide (PI). Neurons were incubated with 50 mM H~2~O~2~ to assess sensitivity to apoptotic stimuli.(I) Quantification of early apoptotic annexin V+/PI*−* neurons. Percentage of labeled cells in total gated cells is shown.(J) Quantification of late-apoptotic Annexin V+/PI+ neurons. Percentage of labeled cells in total gated cells is shown.Mean ± SEM, N = 4 independent experiments and N = 2 technical replicates. Student\'s t test was used to analyze difference between two groups. n.s. not significant. ∗p \< 0.05, ∗∗∗ p \< 0.001. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

*OPA1* Heterozygous NPCs Exhibit a Significantly Altered Transcriptional Signature {#sec2.5}
----------------------------------------------------------------------------------

Next, we addressed whether the impaired formation of DLX1/2+ neurons in *OPA1*+/− cultures could be explained by an altered transcriptional circuitry at the NPC level. Successful formation of day 11 NPCs was verified by the loss of the pluripotency markers OCT4 and NANOG, and the gain of the neural stem cell marker PAX6 ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We then performed RNA-seq analysis in *OPA1+/+* and *OPA1*+/− NPCs after 11 days and 3 weeks of differentiation to elucidate potential transcriptional changes associated with *OPA1* haploinsufficiency. Principal-component analysis was used to assess and visualize the neural differentiation trajectory ([Figure 5](#fig5){ref-type="fig"}A). When we analyzed differentially expressed genes (DEGs) at day 11 *OPA1+/−* versus *OPA1+/+* NPCs, we found *FOXG1* already highly downregulated at this early NPC stage ([Figure 5](#fig5){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}). Another gene we found highly downregulated encodes for TAF9B ([Figure 5](#fig5){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}), a protein that is part of the neuronal core promoter complex and known to regulate the induction of specific neuronal genes ([@bib20]). Moreover, we found *SLITRK2*, a transmembrane protein expressed in proliferative neuroblastic layer of the retina ([@bib6]), to be significantly downregulated in *OPA1*+/− NPCs ([Figure 5](#fig5){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}). In addition, *GABRA2*, the gene coding for GABRA receptor alpha 2; *ATP10D*, a putative phospholipid transporting ATPase; and several neural cell adhesion genes, including *NCAM2*, *PCDHGA3*, and *PCDHGA6,* were also downregulated ([Figure 5](#fig5){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}). Significantly upregulated genes in day 11 *OPA1*+/− versus *OPA1+/+* NPCs included genes coding for neural guidance proteins, such as *SEMA3E*, *SLIT3*, Ephrin type-A receptor 1 (*EPHA1*), and its ligand ephrin A1 (*EFNA1*) ([Figure 5](#fig5){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}).Figure 5*OPA1* Haploinsufficiency Significantly Alters the Transcriptional Circuitry in NPCs(A) Principal-component analysis of hESCs, day 11 and week 3 NPCs, and neurons.(B) Log~2~ fold-change and expression heatmaps of selected down- (green) and up- (red) regulated genes in *OPA1*+/− compared with *OPA1+/+* day 11 NPCs. FC = fold-change. Expression intensities are displayed from blue (low expression) to yellow (high expression).(C and D) (C) *PAX6* and (D) *FOXG1* mRNA levels in day 11 and week 3 NPCs, normalized to transcript levels in *OPA1+/+* hESCs.(E) Immunoblotting showing OPA1, FOXG1, and PAX6 protein expression in NPCs. Beta-actin was used as loading control. N = 3 independent experiments.(F) *ATP10D*, *GABRA2*, *SLITRK2*, *TAF9B,* and *ZNF280D* mRNA expression levels in day 11 NPCs. mRNA expression levels were normalized to transcript levels in *OPA1*+/+ NPCs.(G) *GRHL2*, *GRHL3*, *SIX6*, *VAX1,* and *VSX2* mRNA expression levels in day 11 NPCs. mRNA expression levels were normalized to transcript levels in *OPA1*+/+ NPCs.Mean ± SEM, N ≥ 4 independent samples for each genotype and cell type. Student\'s t test was used to analyze the differences between two groups. n.s. not significant. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. See also [Figures S3](#mmc1){ref-type="supplementary-material"}, [S5](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"}, and [Tables S2](#mmc3){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"}.

DEG analysis of *OPA1*+/− compared with *OPA1+/+* NPCs in week 3 revealed that *FOXG1*, *ATP10D*, *GABRA2*, *SLITRK2, ZNF280D,* and *TAF9B* also remained highly downregulated at this later stage of differentiation ([Figure S5](#mmc1){ref-type="supplementary-material"}B and [Table S3](#mmc4){ref-type="supplementary-material"}). In addition, several genes encoding for TFs involved in primary neurulation, forebrain development, and retinal development were upregulated in *OPA1+/−* NPCs. These included *SIX6*, *GRHL2*, *GRHL3*, *VAX1,* and *VSX2* ([Figure S5](#mmc1){ref-type="supplementary-material"}B and [Table S3](#mmc4){ref-type="supplementary-material"}). Overall, our RNA-seq analyses identified significant alterations in the transcriptional circuitry of *OPA1*+/− NPCs ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}B, [Tables S2](#mmc3){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"}), which can explain the observed altered neuronal cell fate specification.

We then assessed the expression levels of selected genes in more detail. qRT-PCR analysis at three different time points showed continuous increase of *PAX6* mRNA expression levels during NPC derivation ([Figure 5](#fig5){ref-type="fig"}C). *OPA1+/+* NPCs also showed significant upregulation of *FOXG1,* starting 11 days after differentiation ([Figure 5](#fig5){ref-type="fig"}D), a finding in line with its previously described critical role in early brain development ([@bib41]). *OPA1*+/− NPCs expressed similar *PAX6* mRNA levels as *OPA1*+/+ NPCs ([Figure 5](#fig5){ref-type="fig"}C), whereas *FOXG1* transcription was absent in *OPA1*+/− cells during all stages of NPC differentiation ([Figure 5](#fig5){ref-type="fig"}D). This was also true at the protein level ([Figure 5](#fig5){ref-type="fig"}E). In addition, we used qRT-PCR analyses to confirm the downregulation of *ATP10*, *GABRA2*, *SLITRK2*, *TAF9B,* and *ZNF280D* ([Figure 5](#fig5){ref-type="fig"}F) and upregulation of *GRHL2*, *GRHL3*, *SIX6*, *VAX1,* and *VSX2* mRNA expression in *OPA1*+/− compared with *OPA1+/+* NPCs ([Figure 5](#fig5){ref-type="fig"}G). Using a second, independently derived *OPA1*+/− hESC clone \#63, we confirmed reduced OPA1 protein ([Figure S6](#mmc1){ref-type="supplementary-material"}A) and *OPA1* mRNA expression levels in *OPA1+/−* compared with *OPA1+/+* hESC and NPCs, respectively. Moreover, *PAX6* mRNA expression was comparable between genotypes ([Figure S6](#mmc1){ref-type="supplementary-material"}B), whereas *FOXG1* and *TAF9B* mRNA expression levels were also markedly reduced in *OPA1+/−* \#63 NPCs ([Figure S6](#mmc1){ref-type="supplementary-material"}B).

To investigate whether altered transcriptional regulation affects proliferation or cell survival of *OPA1+/−* NPCs, we performed FACS analysis of NPCs labeled with PI. [Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D showed no differences in cell cycle dynamics in *OPA1*+/+ and *OPA1*+/− NPCs. Similarly, Ki-67 expression was also comparable between the two genotypes ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Next, we analyzed the levels of apoptosis in NPCs under normal conditions and upon stimulation with hydrogen peroxide ([Figure S5](#mmc1){ref-type="supplementary-material"}F). We found no significant difference in apoptosis between *OPA1*+/+ and *OPA1*+/− NPCs ([Figure S5](#mmc1){ref-type="supplementary-material"}G), whereas pre-treatment of NPCs with hydrogen peroxide increased Annexin V+/PI+ late apoptotic cells in *OPA1*+/− NPCs ([Figure S5](#mmc1){ref-type="supplementary-material"}H), supporting our results that *OPA1* haploinsufficiency increases the sensitivity of cells to apoptotic stimuli. Collectively, our data demonstrate that OPA1 is essential for proper transcriptional regulation in NPCs, and that *OPA1+/−* NPCs exhibit a developmental defect that causes impaired neural subtype specification.

OPA1 Protects against Aberrant DNA Methylation {#sec2.6}
----------------------------------------------

Recently, it has been shown that metabolic stress and accumulation of mitochondria affect hematopoietic stem cell fate decisions through altered nuclear DNA methylation ([@bib22]). Our transcriptome analyses showed that several genes important for NPC differentiation, GABAergic interneuron formation, and retinal development such as the pioneer transcription factor *FOXG1* were strongly downregulated in *OPA1+/−* NPCs. To address whether this downregulation was caused by epigenetic alterations, we analyzed the CpG content in annotated sequences and found CpG-enriched promoters in genes encoding *FOXG1*, *ATP10D*, *TAF9B*, *SLITRK2*, *GABRA2*, and *ZNF280D*. [Figure 6](#fig6){ref-type="fig"}A depicts the location and CpG-enriched regions in the promoter and 5′ UTR of *FOXG1*. Genomic DNA was isolated from NPCs, bisulfite treated, and the *FOXG1* 5′UTR region was sequenced. We found that all CpG bases within this region were methylated in *OPA1*+/− cells, whereas this was not the case in *OPA1+/+* cells ([Figure 6](#fig6){ref-type="fig"}B). This result demonstrates that DNA hypermethylation was the reason for the observed repression of *FOXG1* transcription. The amplification of the *FOXG1* promoter CpG island was not possible due to the long CpG stretches, which prevented optimal primer design ([Figure 6](#fig6){ref-type="fig"}A). Bisulfite sequencing of the *ATP10D* locus also revealed a high content of methylated promoter CpG in *OPA1*+/− but not in *OPA1+/+* NPCs ([Figures 6](#fig6){ref-type="fig"}C and 6D), further confirming that DNA methylation patterns were altered in *OPA1*+/− NPCs. Taken together, our results suggest that OPA1 is necessary for NPC transcriptional regulation by preventing aberrant methylation.Figure 6OPA1 Protects against Aberrant DNA Methylation(A) Location and sequence of CpG-enriched regions in the *FOXG1* gene promoter and 5′ UTR. ATG is indicated as translation start codon. Numbers denote sequences upstream (−) or downstream (+) of the start codon. The yellow box indicates the 5′ UTR, and blue lines represent CpG enriched regions. CpGs are marked in red.(B) Bisulfite sequencing of the *FOXG1* 5′UTR in *OPA1+/+* and *OPA1*+/− NPCs. Empty circles represent unmodified cytosines, and filled circles represent methylated cytosines.(C) Location and sequence of CpG-enriched regions in the *ATP10D* gene promoter and 5′ UTR. ATG is indicated as translation start codon, and numbers denote sequences upstream (−) or downstream (+) of the start codon. Yellow box indicates the 5′ UTR flanked by a 20-kb intron, and blue lines represent CpG-enriched regions. CpGs are marked in red.(D) Bisulfite sequencing of the *ATP10D* gene promoter in *OPA1+/+* and *OPA1*+/− NPCs. Empty circles represent unmodified CpG bases, and filled circles represent methylated cytosines.(E) *FOXG1* mRNA levels in day 11 *OPA1*+/− NPCs treated with different concentrations of DNMT inhibitor RG108. Mean ± SEM, N = 4 independent experiments with N = 2 technical replicates for each condition. mRNA expression levels were normalized to transcript levels in untreated *OPA1*+/+ NPCs.(F) Succinate and alpha-ketoglutarate levels measured in *OPA1*+/+ and *OPA1*+/− hESCs and day 11 NPCs measured by mass spectrometry analysis. Mean ± SEM, N ≥ 3 independent samples for each genotype and cell type.(G) Oxygen consumption rate changes under mitochondrial stress in *OPA1*+/+ and *OPA1*+/− NPCs. Oligomycin, FCCP, antimycin, and rotenone were sequentially applied. Mean ± SEM, N = 3 independent experiments.(H) Basal respiration rates, maximum respiration rates, and ATP production in *OPA1+/+* and *OPA1*+/− NPCs. Mean ± SEM, N = 3 independent experiments were performed and N ≥ 40 technical replicates were analyzed for each genotype.(I) Representative flow cytometry analysis of *OPA1*+/+ and *OPA1*+/− NPCs labeled with the hydrogen peroxide-sensitive oxidative stress indicator CM-H2DCFDA. Unlabeled NPCs (−) were used as negative control. NPCs that were incubated with 0.5 mM H~2~O~2~ were used as positive control.(J) Quantification of flow cytometry measurements in *OPA1+/+* and *OPA1*+/− NPCs. Arithmetic mean values were normalized to the values of labeled *OPA1+/+* NPCs. Mean ± SEM, N ≥ 4 independent experiments and N = 2 technical replicates.(K) *CAT* mRNA expression levels in day 11 *OPA1*+/+ and *OPA1*+/− NPCs. mRNA expression levels were normalized to transcript levels in *OPA1*+/+ NPCs.Mean ± SEM, N ≥ 3 independent samples were assessed for each genotype. Student\'s t test was used to analyze the difference between two groups. n.s. not significant. ∗p \< 0.05, ∗∗∗p \< 0.001. See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

Next, we tested whether inhibition of DNA methylation can restore the transcriptional silencing in *OPA1*+/− NPCs. Strikingly, incubation of cells with the DNA methyltransferase (DNMT) inhibitor RG108 during neural differentiation resulted in a partial rescue of *FOXG1* expression in *OPA1*+/− NPCs, demonstrating that the transcriptional silencing caused by *OPA1* haploinsufficiency could be rescued by inhibiting DNMTs and preventing DNA methylation ([Figure 6](#fig6){ref-type="fig"}E). To determine whether DNA methylation and hydroxymethylation levels were affected on a global level in *OPA1+/−* NPCs, we used mass spectrometry-based quantification and found similar total methylation (5me(dC)) and hydroxymethylation (5hm(dC)) levels in *OPA1*+/+ and *OPA1*+/− NPCs ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Moreover, immunoblotting for DNMT3A and DNMT3B proteins showed similar expression levels between different genotypes, suggesting that reduced OPA1 levels lead to loci-specific rather than global DNA methylation changes ([Figure S7](#mmc1){ref-type="supplementary-material"}B).

To further explore the potential cause for the observed loci-specific changes in DNA methylation, we analyzed the concentration of the small metabolites S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH), which serve as substrates for DNMTs. Using mass spectrometry analysis we demonstrate that the overall SAM/SAH ratio in NPCs of both *OPA1*+/− and *OPA1*+/+ genotypes was significantly higher than in hESCs, indicating an overall higher methylation capacity in NPCs ([Figure S7](#mmc1){ref-type="supplementary-material"}C). However, the overall SAM/SAH ratio was not altered when OPA1 was reduced ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Next, we quantified succinate and alpha-ketoglutarate levels in hESCs and NPCs. Again, there were no significant changes in succinate and alpha-ketoglutarate levels in *OPA1*+/− versus *OPA1*+/+ cells ([Figure 6](#fig6){ref-type="fig"}F), indicating that altered availability of these small metabolites is likely not the reason for the observed changes in DNA methylation.

When analyzing the mitochondrial energy metabolism in NPCs, we found a small but significant increase in basal respiration and ATP production levels in *OPA1*+/− compared with *OPA1*+/+ NPCs ([Figures 6](#fig6){ref-type="fig"}G and 6H). In addition, flow cytometry analysis showed significantly increased ROS levels in *OPA1*+/− NPCs ([Figures 6](#fig6){ref-type="fig"}I and 6J), further confirming our results in hESC and neurons. In line with the observed increased oxidative stress level in *OPA1+/−* NPCs, we found catalase (*CAT*) and *FOXC1* mRNA expression levels significantly upregulated in day 11 *OPA1*+/− NPCs ([Figure 5](#fig5){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}). Catalase is a peroxisomal enzyme protecting cells against oxidative stress, and FOXC1 is a stress-responsive TF that provides resistance to oxidative stress in the eye ([@bib34]). The upregulation of *CAT* expression was confirmed by qRT-PCR in NPCs derived from two independent *OPA1*+/− lines ([Figures 6](#fig6){ref-type="fig"}K and [S6](#mmc1){ref-type="supplementary-material"}B).

Patient-Derived iPSC Harboring a Pathogenic *OPA1* Mutation Exhibit Increased ROS Levels and Downregulation of *FOXG1* {#sec2.7}
----------------------------------------------------------------------------------------------------------------------

Heterozygous mutations in OPA1 are a common cause of ADOA ([@bib17], [@bib3]). To ensure that the changes detected in our genetically engineered hESCs were not caused by off-target effects by CRISPR-Cas9, we generated induced pluripotent stem cells (iPSCs) derived from two male donors who carry the inactivating *OPA1* c.2873_2876delTTAG mutation. First, we assessed *OPA1* mRNA expression and found that mRNA expression levels were reduced by 35%--40% compared with *OPA1*+/+ NPCs ([Figure 7](#fig7){ref-type="fig"}A). Next, we found that *PAX6* mRNA expression levels were similar between patient iPSC- and hESC-derived NPCs ([Figure 7](#fig7){ref-type="fig"}B). Moreover, *FOXG1* ([Figure 7](#fig7){ref-type="fig"}C) and *CAT* ([Figure 7](#fig7){ref-type="fig"}D) mRNA expression levels were down- and upregulated in patient iPSC-derived NPCs, respectively. Next, we used the ROS indicator CM-H2DCFDA and further demonstrated that ROS levels were markedly increased in patient-derived iPSCs ([Figures 7](#fig7){ref-type="fig"}E and 7F). Taken together, these results indicate that *OPA1* haploinsufficiency is accompanied by aberrant nuclear DNA methylation and changed transcriptional circuitry.Figure 7Patient-Derived iPSCs Harboring a Pathogenic *OPA1* Mutation Exhibit Increased ROS Levels and Downregulation of *FOXG1*(A--D) (A) *OPA1* mRNA, (B) *PAX6*, (C) *FOXG1,* and (D) *CAT* mRNA expression levels in day 11 NPCs differentiated from iPSC lines derived from two donors diagnosed with ADOA.(E) Representative flow cytometry analysis of *OPA1*+/+ hESCs, iPSC \#1, and iPSC \#2 labeled with the oxidative stress indicator CM-H2DCFDA. Unlabeled hESCs (−) were used as negative control. hESCs and iPSCs that were incubated with 0.5 mM H~2~O~2~ were used as positive control.(F) Quantification of flow cytometry measurements in iPSC \#1 and iPSC \#2. Arithmetic mean values were normalized to the values of labeled *OPA1+/+* hESCs.Mean ± SEM, N = 3 independent experiments and N = 2 technical replicates. Student\'s t test was used to analyze difference between two groups. n.s. not significant. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Discussion {#sec3}
==========

Our study shows for the first time that *OPA1* haploinsufficiency correlates with aberrant nuclear DNA methylation patterns as well as a significantly altered transcriptional circuitry and differentiation potential of NPCs ([Figure 8](#fig8){ref-type="fig"}).Figure 8Schematics Illustrating the Metabolic and Epigenetic Changes in *OPA1* Haploinsufficient Cells, Which May Contribute to Altered Neuronal Differentiation

The role of OPA1 during physiologic and pathologic neural development remains incompletely understood. We observed a severe loss of DLX1/DLX2-positive neurons when OPA1 protein levels were reduced by 50%. Studies using mouse models have previously shown that Dlx1 and Dlx2 are expressed in the developing retinal neuroepithelium ([@bib18]) and are needed for the terminal differentiation of late-born RGCs ([@bib13]). Moreover, *Dlx1*/*Dlx2* double-null mice exhibit up to 30% reduced numbers of RGCs, whereas formation of other retinal neuronal cell types is not affected. In addition to Dlx1/2, loss of *Sfrp1* expression ([@bib19]) and forced expression of NeuroD factors ([@bib10]) are known to dysregulate retinal cell diversity in mice and chicken. Strikingly, we find impaired expression of DLX1/2 and SFRP1 as well as an upregulation of NEUROD4 when OPA1 levels are reduced, which may explain the loss of RGCs observed in patients with ADOA.

Our transcriptome analysis in NPCs substantiates the relevance of balanced OPA1 levels for proper neural cell homeostasis. One TF that we find consistently repressed in our study is the pioneer factor *FOXG1,* which is predominantly expressed in the developing neuroepithelium, retina, and optic chiasm. A previous study found that FOXG1 is crucial for GABAergic neuronal formation and retinal development because *Foxg1*−/− mice exhibit eye abnormalities ([@bib41]). Importantly, *Foxg1−/−* telencephalic progenitors fail to generate Dlx1-and Dlx2-positive neurons ([@bib41]). Other evidence that links FOXG1 to the generation of DLX1/2+ neurons stems from a recent report demonstrating that *FOXG1* upregulation is responsible for the overproduction of GABAergic neurons in brain organoids derived from iPSCs obtained from patients with autism spectrum disorder ([@bib32]). In addition, studies in mice and chicken showed that loss of *Foxg1* expression results in RGC axonal misprojection and pathfinding defects ([@bib42], [@bib38]). Our gene expression analyses in hESC-derived NPCs and neurons also suggest that FOXG1 is a direct regulator of human GABAergic neuronal formation and retinal development.

Recently, iPSCs derived from patients carrying heterozygous mutations in *OPA1* and having an inherited form of Parkinson disease (PD) were generated and used to investigate dopaminergic neuronal development. The authors found fragmented mitochondria, a decrease in respiration, and a decrease in neuronal viability, as well as an increase in ROS ([@bib23]). Although we also observe an increase in ROS and sensitivity to apoptotic stimuli, we only find subtle changes in mitochondrial morphology including increased intercristae distance, reduced circumference, and a trend to more fragmented mitochondria in *OPA1+/−* hESCs. Overall, the phenotype in PD patient-derived iPSCs seems more severe than the one observed in *OPA1* haploinsufficient hESCs and ADOA patient-derived iPSCs. It is possible that this is because PD is a more complex disease with potential additional epigenetic and genetic changes in contrast to familial optic atrophy with a single-gene mutation. Other studies also show significant mitochondrial fragmentation in mouse cerebellar granule ([@bib24]) and HeLa cells ([@bib5]). In these studies OPA1 expression was almost completely abolished, whereas in our cells 50% OPA1 proteins remain, which might explain the mild changes in mitochondrial morphology in our cells. In line with this, a recent study using *OPA1* haploinsufficient iPSCs derived from patients with syndromic parkinsonism also shows only subtle changes in the mitochondrial ultrastructure in iPSC-derived dopaminergic neurons ([@bib25]).

A fascinating question is how *OPA1* haploinsufficiency impacts on nuclear DNA methylation at specific sites, such as the *FOXG1* and *ATP10D* promoters. Epigenetic pathways and transcriptional regulation are influenced by non-protein-coding RNA molecules. For instance, the murine long non-coding RNA Kcnq1ot1 recruits the DNA methyltransferase Dnmt1 to CpG islands of imprinted genes ([@bib35]), and the natural antisense transcript AS1DHRS4 controls localization of DNMTs to the promoter regions of transcripts DHRS4L1 and DHRS4L2 ([@bib29]). Given that the DNA methylation changes we observe in *OPA1+/−* NPCs are loci specific, it is possible that expression and availability of non-coding RNAs that regulate DNA methylation is affected in *OPA1+/−* NPCs.

Enzymes catalyzing epigenetic changes require specific metabolites as sources of acetyl or methyl groups ([@bib26], [@bib30]). Small metabolites such as SAM, SAH, and alpha-ketoglutarate establish a link between mitochondrial metabolism and epigenetics ([@bib33]). We find similar SAM/SAH and succinate/alpha-ketoglutarate levels in *OPA1+/−* and *OPA1+/+* cells, suggesting that the observed changes in DNA methylation are not caused by alterations of these small metabolites. Previously, it has been shown that oxidative stress causes aberrant DNA methylation and transcriptional silencing ([@bib37]). The authors reveal that DNMT1 is targeted to damaged chromatin, forming a complex with DNMT3B and polycomb repressive complex 4 ([@bib37]), and show that hydrogen peroxide treatment causes a relocalization of these proteins to promoter CpG islands. Importantly, we find that *OPA1* haploinsufficiency results in increased oxidative stress and ROS accumulation in *OPA1*+/− hESCs and ADOA patient-derived iPSCs. It is well possible that altered ROS levels play a role in the DNA methylation changes we described. Supporting this notion, mitochondrial dysfunction and increased ROS levels have recently been described to cause specific promoter hypermethylation and decreased expression of microRNA-663 in cancer cell lines ([@bib7]). Exogenous and endogenous ROS are also known to affect neural stem cell renewal and proliferation. For instance, Le Belle et al. show that brain-derived neural progenitors maintain a high ROS status and are responsive to ROS stimulation leading to posttranslational oxidative inactivation of PTEN, and activation of PI3K/Akt signaling pathway, which is required for NPC self-renewal ([@bib27]). Another study by Chui et al. demonstrated that selective removal of histone-lysine N-methyltransferase *PRDM16* in NPCs leads to abnormal neuronal composition and organization in the mouse brain by inducing excessive ROS ([@bib11]). Our results together with these studies suggest that activation of specific pathways by ROS signaling is context dependent and may influence various pathways during cell fate specification.

In conclusion, we provide evidence that *OPA1* haploinsufficient cells exhibit increased oxidative stress, aberrant nuclear DNA methylation, and a significantly altered transcriptional circuitry.

Limitations of the Study {#sec3.1}
------------------------

Although we addressed DNA methylation changes in the promoter regions of selected down-regulated genes, we did not explore this for up-regulated genes or in a global context. Moreover, we did not assess cell death under stress conditions in iPSC-derived neurons, and performed the mitochondrial respiration assay in two not three independent experiments, although each with 10--40 replicates. In addition, although we observed an increase in ROS that might contribute to the aberrant DNA methylation, we were not able to identify the exact mechanism by which *OPA1* haploinsufficiency contributes to these changes in nuclear DNA methylation. Defining primary versus secondary changes related to OPA1 will be exciting to explore in the future.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Judith Staerk (<judith.staerk@ncmm.uio.no>).

### Materials Availability {#sec3.2.2}

There may be restrictions or delays to the availability of hESC and iPSC lines due to our need to maintain the stock and patient consent. Availability of iPSC lines will require a Materials Transfer Agreement.

### Data and Code Availability {#sec3.2.3}

Access to data that support the findings of this study are available from the authors on reasonable request. RNA-seq information including all raw data has been deposited at Gene Expression Omnibus under [GSE117976](ncbi-geo:GSE117976){#intref0015}: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117976>.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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========================

Document S1. Transparent Methods, Figures S1--S7, and Tables S4 and S5Table S1. Deseq2 Output of Differentially Expressed Genes in hESC-Derived *OPA1+/−* Compared with *OPA1+/+* Neurons, Related to Figure 3Number of normalized reads, fold-change, p value, and adjusted p values are shown. Genes in bold were selected for the heatmaps shown in [Figure 3](#fig3){ref-type="fig"}A.Table S2. Deseq2 Output of Differentially Expressed Genes in *OPA1+/−* Compared with *OPA1+/+* NPCs at Day 11 (D11), Related to Figure 5Number of normalized reads, fold-change, p value, and adjusted p values are shown. Genes in bold were selected for the heatmaps shown in [Figure 5](#fig5){ref-type="fig"}B.Table S3. Deseq2 Output of Differentially Expressed Genes in *OPA1+/−* Compared with *OPA1+/+* NPCs at Week 3 (W3), Related to Figures 5 and S5Number of normalized reads, fold-change, p value, and adjusted p values are shown. Genes in bold were selected for the heatmaps shown in [Figure S5](#mmc1){ref-type="supplementary-material"}B.
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